Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Etretinate. Persistent serum levels after long-term therapy.

J J DiGiovanna1, L A Zech, M E Ruddel

  • 1Dermatology Branch, National Institutes of Health, Bethesda, MD 20892.

Archives of Dermatology
|February 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What is the best method of rectovaginal fistula repair? A 25-year single-center experience.

Techniques in coloproctology·2021
Same author

Bilateral adrenal hemorrhage after colectomy for perforated diverticulitis: A case report.

International journal of surgery case reports·2021
Same author

Thyroid nodules in xeroderma pigmentosum patients: a feature of premature aging.

Journal of endocrinological investigation·2020
Same author

Robotic transanal excision of a large rectal polyp - a video vignette.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2020
Same author

Training and accrediting international surgeons.

The British journal of surgery·2019
Same author

Molecular diagnosis of xeroderma pigmentosum variant in an isolated population: the interface between precision medicine and public health.

The British journal of dermatology·2017
Same journal

Scoring With SCORTEN-Reply.

Archives of dermatology·2017
Same journal

Comparison of Early and Late Latent Syphilis- Colorado, 1991.

Archives of dermatology·2016
Same journal

Case of Rhinoscleroma.

Archives of dermatology·2016
Same journal

Cutaneous Fungal Infections.

Archives of dermatology·2016
Same journal

An Ulcerated Plaque in a Gay Man.

Archives of dermatology·2016
Same journal

Solitary Violaceous Nodule on the Face.

Archives of dermatology·2016
See all related articles

Etretinate therapy can lead to detectable serum concentrations for over two years post-treatment. Overweight patients exhibit slower etretinate elimination and prolonged presence in the body.

Area of Science:

  • Pharmacology
  • Dermatology
  • Clinical Chemistry

Background:

  • Etretinate is a retinoid medication used for long-term dermatological therapy.
  • Retinoids are known to have prolonged elimination phases due to their lipophilic nature.
  • Understanding the pharmacokinetics of etretinate is crucial for managing patient care after treatment cessation.

Purpose of the Study:

  • To measure serum etretinate concentrations in patients after long-term therapy.
  • To determine the half-life of etretinate during its late-phase elimination.
  • To investigate the influence of body fat on etretinate's pharmacokinetic profile.

Main Methods:

  • Serum etretinate levels were quantified in 47 patients from 1 to 244 weeks post-discontinuation.
  • Late-phase elimination half-lives were calculated from sequential serum concentrations in eight patients.

Related Experiment Videos

  • Patient body weight deviations from ideal were assessed to estimate excess body fat.

    • Main Results:

    • Detectable serum etretinate concentrations persisted for over two years (up to 150 weeks) in some patients.
    • The median half-life for late-phase elimination was 12.5 weeks (range: 5.3–24.8 weeks).
    • Overweight patients showed slower elimination, higher serum concentrations, and later clearance of etretinate.

    Conclusions:

    • Etretinate exhibits a very long elimination half-life, with detectable levels persisting for years.
    • Body fat significantly impacts etretinate pharmacokinetics, leading to slower clearance in overweight individuals.
    • Clinical monitoring and patient counseling should consider the prolonged presence of etretinate in the body, especially in patients with higher body fat.